**Mini review**

Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

Yi-Ying Wu1,2, Ming-Shan Chen3, Muhammad Munir4, Hung-Jen Liu 1, 2,5, 6, 7\*

1 Institute of Molecular Biology, National Chung Hsing University, Taichung, Taiwan

2 The iEGG and Animal Biotechnology Center, National Chung Hsing University, Taichung,

 Taiwan

3Department of Anesthesiology, Ditmanson Medical Foundation Chia-Yi Christian Hospital,

Chia-Yi, Taiwan

4Department of Biomedical and Life Sciences, Lancaster University, Lancashire, UK

5Rong Hsing Research Center for Translational Medicine, National Chung Hsing University,

Taichung, Taiwan

6Ph.D Program in translational Medicine, National Chung Hsing University, Taichung, Taiwan

7Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan

\*To whom correspondence should be addressed: Hung-Jen Liu, Institute of Molecular

Biology, National Chung Hsing University, Taichung 402, Taiwan. Phone: 886-4-22840485 ext. 243; Fax: 886-4-22874879; E-mail address: hjliu5257@nchu.edu.tw.

**Abstract**

Recent reports have revealed that oncolytic viruses (OVs) play a significant role in cancer therapy. The infection of OVs such as oncolytic vaccinia virus (OVV), vesicular stomatitis virus (VSV), parvovirus, mammalian reovirus (MRV), human adenovirus, Newcastle disease virus (NDV), herpes simplex virus (HSV), avian reovirus (ARV), and Orf virus (ORFV) offer unique opportunities in immunotherapy through diverse and dynamic pathways. This mini-review focuses on the mechanisms of OVs mediate virotherapy and their effects on immunogenic cell death (ICD), apoptosis, autophagy and regulation of the immune system.

**KEYWORDS**

oncolytic viruses, virotherapy, immune system, apoptosis, autophagy, immunogenic cell death

**Introduction**

Oncolytic viruses (OVs) are new class of natural means of immunotherapy and hold promising future prospects in oncology. OVs are being evaluated as immunotherapies for a variety of advanced malignancies. These have been proposed as potential cancer treatments by inflaming the tumor microenvironment (TEM) and directly killing tumor cells. The oncolytic HSV in immunotherapy cracks tumor cells without causing damage to normal cells (Ma et al., 2018). The therapeutic promise of OVs depends on their ability to selectively kill tumor cells and induce antitumor immunity while protecting healthy cells. OVs-mediated tumor destruction is now recognized as a powerful tool to aid the development of anti-tumor immunity (Glorioso et al., 2021). The perfect OV should eliminate cancer cells through a combination of three mechanisms, including the induction of apoptosis, pro-inflammatory cytokines, and interferons (Schiller et al., 2012; Mahmoud et al., 2015; Frumence et al., 2016). In addition to directly killing tumor cells, OVs activate immune responses or express healing factors to elevate antitumor efficacy, thereby enhancing efficacy of cancer immunotherapies (Sobhanimonfared et al., 2020; Yang et al., 2021). Additionally, OVs-mediated apoptosis may trigger anticancer immune responses in TEM (Ma et al., 2020). OV immunotherapy began in the 1950s when the virus was thought to invade and destroy cancer cells (Gebremeskel et al., 2021; Ang et al., 2022; Ripp et al., 2022). More recently, OVs have been at the forefront of cancer immunotherapy. Human adenovirus, the first and most potent virus, has been suggested for oncolytic immunotherapy (Mondal et al., 2020). Many studies have developed a number of strategies to stimulate antitumor immunity and to productively modulate the TME for potent and sustained anti-tumor immune cell activity (Workenhe and Mossman, 2014; Takasu et al., 2016; Guo et al., 2017; Mardi et al., 2022; Zhu et al., 2022). OVs may be armed to express T helper type 1 (Th1)-stimulatory cytokines/chemokines or co-stimulators to recruit and maintain potent antitumor immunity into the TME to focus their therapeutic activities at the site of disease. The combination of OV with immunomodulatory drugs or antibodies that repair the TME has proven very promising in early studies. Furthermore, the combination of OV with other immunotherapeutic virotherapy (e.g. CAR T cells, equipped with bispecific T cell engagers, and prime-boost cancer vaccines) has also yielded promising initial findings (Ma et al., 2020).

**Oncolytic virus and immunology**

OVs can be as an adjunct to immune checkpoint inhibition (Ripp et al., 2022). OV has been combined with immune checkpoint inhibitors, with strong anti-tumor efficacy observed in pilot evaluations (Wang et al., 2020; Christie et al., 2021; Ripp et al., 2022). Selective destruction of tumor tissues by OVs leads to antigen-agnostic enhancement of neoantigen-specific cytotoxic T cell responses, making OVs ideal companions for checkpoint blockade therapy (Russell and Barber, 2018). Systemic administration of tumor necrosis factor-armed myxoma virus plus immune checkpoint inhibitors eliminates lung metastatic murine osteosarcoma (Christie et al., 2021). Engineered OVs expressing a PD-L1 inhibitor activate tumor neoantigen-specific T cell responses (Wang et al., 2020). Oncolytic activity of Zika virus requires cytotoxic T lymphocytes and is enhanced by immune checkpoint blockade against Glioblastoma (GBM) (Nair et al., 2021). Chimeric antigen receptor (CAR) T cells and OVs have emerged as promising cancer immunotherapies for cancer treatment (Watanabe et al., 2021). While immune checkpoint blockade has been approved for a wide range of solid tumors, other immunotherapies such as CAR T cells and T-cell redirecting bispecific T-cell engagers (BiTEs) have been approved specifically for hematologic malignancies but less studied in solid tumors. BiTEs are an innovative class of immunotherapies that redirect T cells to tumor surface antigens and OV-BiTEs can serve as a blueprint for diverse OV-based cancer virotherapies (Heidbuechel and Engeland, 2021).

Other immunotherapies, such as cancer vaccines, cytokines, CAR T cells therapy, small molecules, and OVs, are currently in use against colorectal cancer (Feng et al., 2021). Development of successful CAR T cells therapy needs identification of specific tumor-associated antigens, as the primary target for CAR T cells binding and activation. Many solid tumors carry well-characterized oncogenes which play a critical role in tumor cell proliferation, migration, and survival. These oncogenes are ideal targets for CAR T cells therapy, particularly when the oncogene is expressed at low levels in normal tissues. More recently, it was found that interleukin (IL)-7-loaded oncolytic adenovirus elevates CAR T cells therapy for GBM (Huang et al., 2021). The type 1 of HSV which expresses IL-12 efficiently replicates and kills human colorectal cancer cells (Haghighi-Najafabadi et al., 2021). IL-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) from an engineered oncolytic HSV have a synergistic effect, which boosts the immune response to enhance their antitumor effects in a B16-F10 murine melanoma model (Kim et al., 2021). Combination of IL-10 and oncolytic adenovirus demonstrated to enhance antitumor efficacy by cytotoxic T cells (Chen et al., 2021). Avian virus, NDV, can induce tumor necrosis factor-alpha and augment its cytotoxicity as an antineoplastic agent (Lorence et al., 1988). Recently, IL-21 arming was reported to enhance the antitumor activity of OVV in monotherapy and combination immunotherapy (Chen et al., 2021). Thus, OVV gene modification and cytokines expression can influence tumor killing, tumor infection, and immune response ( Inoue et al., 2021).

Although OVs-derived type I interferons limit CAR-T cells therapy (Evgin et al., 2020), however, OVs-mediated expansion of bispecific CAR T cells can improve efficacy in solid tumors in mice (Evgin et al., 2022). OV-accompanied CAR T cells are forced to overcome solid tumor challenges (Guedan and Alemany, 2018). Furthermore, the study by Xiao et al suggested that the CDK4/6 inhibition enhances OVs (VSVΔ51 and Zika virus) efficacy by T-cells activation and potentiating tumor-selective cells killing in refractory GBM (Xiao et al., 2022). Oncolytic H-1 parvovirus activates helper but not regulatory human CD4+ T cell responses (Moralès et al., 2012). Smac-Mimetics (SMs) have entered clinical trials in hematology and solid cancers, but unfortunately, results have been variable and limited (Morrish et al., 2020). OVs and SMs can synergistically drive anticancer T cell responses through complementary mechanisms (Kim et al., 2017). Oncolytic measles virus therapy enhances tumor associated antigens-CD8+ lymphocytes responses in patients with multiple myeloma (Packiriswamy et al., 2020). Interestingly, natural killer T cell immunotherapy combined with oncolytic VSV or MRV therapy significantly improved survival in mouse models of breast and ovarian cancer metastasis (Gebremeskel et al., 2021). HSV type 2-based OV acts as an attractant to guide the migration of adoptively transferred T cells to tumor sites (Fu et al., 2015). Recently, ORFV infection of lung cancer cells induced tumor cell oncolysis to release risk-associated molecular patterns and promoted dendritic cell maturation and CD8+ T cell infiltration in tumors by enhancing C-X-C motif chemokine ligand 16 (CXCL16) secretion (Wang et al., 2022). The report contributes to the understanding of the molecular mechanism of ORFV oncolysis and contributes to the development of new therapies for lung cancer (Wang et al., 2022). The immunosuppressive state of the breast cancer TME makes it difficult to treat with immunotherapy, but the chimeric oncolytic adenovirus armed with the chemokine regulated after activation, expressed and secreted by normal T cells (RANTES)/ CC chemokine ligand 5 (CCL5) appears to be a promising drug candidate for the treatment of breast cancer (Ang et al., 2022).

Combination of oncolytic measles vaccine virotherapy and NK cell therapy results in enhanced oncolysis of A673 and HT1080 pediatric sarcoma cells (Klose et al., 2019). Recently, it was demonstrated that the combination of oncolytic herpes simplex 1-based-expressing human IL15/IL15Rα sushi domain fusion protein (named OV-IL15C) and off-the-shelf epidermal growth factor receptor (EGFR)-CAR NK cells triggers strong antitumor responses in GBM (Ma et al., 2021). This team demonstrated that OV-IL15C plus EGFR-CAR NK cells synergistically inhibit tumor growth and improve survival in comparison to monotherapy, correlating with increased intracranial infiltration and activation of NK and CD8+T cells and increased persistence of CAR NK cells in an immunocompetent model (Ma et al., 2021).

Mesenchymal stem cells along with OVs are joining forces against cancer (Moreno, 2021). Furthermore, combination of menstrual blood mesenchymal stem cells loaded with oncolytic adenovirus and peripheral blood mononuclear cells (PBMCs) enhanced antitumor efficacy (Moreno et al., 2019). Delivery of OVV found to match allogeneic stem cells and overcome key innate and adaptive immune barriers (Draganov et al., 2019). OV has been engineered to enforce leptin expression to reprogram tumor-infiltrating T-cell metabolism, thereby promoting tumor clearance (Rivadeneira et al., 2019). Immunomodulation by telomerase-specific oncolytic adenovirus synergistically enhances the antitumor efficacy of anti-programmed cell death 1 (PD-1) antibodies (Kanaya et al., 2020). Viro-antibody immunotherapy is also engineering OVs for genetic delivery of diverse antibody-based immunotherapies (Kontermann et al., 2021). Oncolytic HSV type 1 virus expressing full-length antibodies enhances the antitumor innate immune response against GBM and is capable of lysing tumor cells (Xu et al., 2021). Bispecific antibody (BsAb)-armed OVs can efficiently modulate TEM. BsAbs expressed by oncolytic HSV type 2 have been proved to convert heterologous T cells into homogeneous tumor-killing cells (Jin et al., 2022). Reshaping the TEM with OVs can blockade the immunosuppressive nonmetabolic circuitry, and positively regulates the immune synapse (Nguyen et al., 2022).

**Oncolytic viruses-induced immunogenic cell death (ICD)**

 Apoptosis, pyroptosis, necrosis, ferroptosis and autophagy-dependent cell death belongs to cell death pathways identified so far, all of which have been classified as an ICD (Inoue and Tani, 2014). ICD is a type of cancer cell death induced by certain physical and chemical therapies, such as OVs, chemotherapeutic drugs, radiation therapy and photodynamic therapy (Ahmed and Tait, 2020). OVs are naturally occurring or genetically engineered viruses that are administered intralesionalally or intravenously to induce tumor cell death and activate antitumor immune responses. After entering tumor cells, OVs can induce innate and adaptive immune responses, thereby acting to eradicate cancer cells within the TME. Lysis of tumor cells can release pathogen-associated molecular patterns (PAMPs), such as viral nucleic acids and proteins, and damage-associated molecular patterns (DAMPs), such as heat shock proteins (HSPs) and high mobility group box 1b (HMGB1), stimulating innate immune response. NK cells and macrophages in the TME can recognize PAMPs/DAMPs through cell surface pattern recognition receptors (PRRs) to secrete inflammatory cytokines such as IFN-γ, IL-12, IFN-α, TNF-α and IL-6, which can then induce antiviral and antitumor immune responses and recruit other innate immune cells from peripheral lymphoid organs (Saha et al., 2016). Furthermore, release of tumor-associated antigens or tumor-specific antigens and antigen presentation by antigen-presenting cells (APCs) following tumor cell lysis leads to adaptive immune responses and antigen-specific cytotoxic T cell and T helper cells. These tumor-reactive T cells can then induce ICD in tumor cells, a mechanism that has been demonstrated in preclinical study (Angelova et al., 2014).

 OVs often induce ICD of cancer cells, and they may interact directly with immune cells as well to trigger antitumor immunity (Mardi et al., 2022; Takasu et al., 2016; Workenhe and Mossman, 2014; Zhu et al., 2022). OVs engage the immune system while they replicate within solid tumors. OVs replicate in cancer cells and release tumor antigens, which are perceived as dangerous because of simultaneous expression of PAMPs that activate APCs. Therefore, OVs provide the target antigens and danger signals required to induce adaptive immune responses. Oncolytic virotherapy and cancer ICD sharpen swords for improving cancer treatment strategies (Workenhe and Mossman, 2014). Alongside traditional ICD inducers such as anthracycline chemotherapeutics and radiation, OVs have emerged as new members of this class of therapeutics, which are increasingly promising outcomes in cancer patient clinical trials (Workenhe and Mossman, 2014). OVs are also attractive candidates for creating ICD, biological barriers limiting their success in the clinic, and groundbreaking strategies to potentiate ICD and antitumor immunity with rationally designed OV-based combination therapies (van Vloten et al, 2018). OVs have been engineered or combined with other ICD inducers to promote more efficient T cell cross-priming and, in many cases, disrupt functional immune tolerance. Current therapeutic concepts against aggressive malignancies require induction of ICD characterized by exposure of calreticulin and release of ATP and HMGB1 from dying cells. Recent studies have shown that oncolytic NDV causes HMGB1, calreticulin exposure and, ATP secretion and HSP70/90 release, leading to ICD induction in melanoma cells (Shao et al., 2019). Furthermore, Wang et al. revealed that an oncolytic NDV strain FMW (NDV/FMW), triggers the production and exposure of various ICD markers in prostate cancer cells, including HSP70/90, HMGB1, and calreticulin. They also proposed that combining STAT3 inhibition with oncolytic NDV could enhance NDV-based anticancer effects in prostate cancer (Wang et al., 2020). In pancreatic ductal adenocarcinoma (PDAC) cells infected with oncolytic parvovirus H-1PV, all infected cells released only HMGB1, whether they were non-dead cells, necrotic cells or cells that died by one of the programmed death pathways, including moderate apoptosis (Angelova et al., 2014). It was found that complementary induction of ICD by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer sustained induction of HMGB1 secretion raises the possibility that this response may be characteristic of a general alarm phenomenon (release of IL-1β suggests that a danger-sensing inflammasome platform may be involved) of H-1PV interaction with host cells (Angelova et al., 2014). Immune checkpoint inhibitors, such as anti-PD-1 antibodies, are able to improve clinical outcomes in certain cancers. Due to poor immune response, PDAC is refractory to PD-1 blockade therapy. More recently, it has been demonstrated the p53-expressing telomerase-specific oncolytic adenovirus OBP-702 induces ICD and anti-tumor immune responses in human PDAC cells with different p53 status (Araki et al., 2022). Oncolytic adenovirus OBP-702 promotes ICD with secretion of extracellular adenosine triphosphate and HMGB1 by regulating p53-induced apoptosis and autophagy. The OBP-702 significantly elevates the tumor infiltration of cytotoxic T cells and the anti-tumor efficacy of PD-1 blockade in a subcutaneous murine PDAC cells (PAN02) syngeneic tumor model (Araki et al., 2022).

 OVs have an intrinsic ability to provide the correct signals to trigger anti-tumor immune responses, both by delivering virus-derived innate signals and by ICD. It was found that oncolytic HSV-1 induces ICD resulting in maturation of CD1c (BDCA-1)+ myeloid dendritic cells (Kalus et al., 2022). Molecules necessary for the induction of ICD are called DAMPs, which induce potent anti-cancer immunity. The oncolytic HSV-1 also can induce ICD in squamous cell carcinoma cells (Takasu et al., 2016). Oncolytic NDV-induced ICD release DAMPs, and causes resistance in malignancies. It has been demonstrated that the STAT3 signaling contributes to oncolytic NDV-induced ICD in melanoma cells (Shao et al., 2019) and that targeting STAT3 enhances NDV-induced ICD in prostate cancer cells (Wang et al., 2020). Talimogene laherparepvec (T-VEC) is a type of HSV modified to selectively grow in tumor cells and express the immunostimulatory transgenic GM-CSF (Hu et al., 2006). The mechanism of action of T-VEC has not been fully elucidated but is thought to induce ICD and activation of host anti-tumor immunity. A recent report suggested that OVs immunotherapy induces ICD and overcomes stimulator of interferon genes deficiency in melanoma (Bommareddy et al., 2019).

Current treatments fail to significantly improve patient survival, which is often limited to less than 1 year after diagnosis. Virotherapy, based on the use of OVs, exerts an anticancer effect through direct cell lysis and the OVs dl 922-947 triggers ICD in mesothelioma, reduceing xenograft growth (Di Somma et al., 2019). CAR T cells therapies are a promising and rapidly expanding treatment option for a variety of human malignancies. Despite continued progress in CAR T cells therapies in hematological malignancies, application of this therapeutic strategy in solid tumors has been hampered by antigenic heterogeneity, suboptimal CAR T-cell trafficking, and the immunosuppressive features of the TME. Oncolytic virotherapy is a new type of cancer therapy that uses competent or genetically modified OVs to preferentially proliferate in tumor cells. Combining OV with CAR T cells is a promising candidate to overcome the current shortcomings of CAR T cell application in tumors by triggering ICD in cancer cells (Mardi et al., 2022). OVs therapy leads to ICD of virus-infected tumor cells and this has been shown in preclinical models to enhance the CD8+ T cell response against tumor-associated antigens, leading to enhance tumor antigen-specific T-cell responses in patients with multiple myeloma (Packiriswamy et al., 2020). In addition to direct oncolysis, OVs trigger ICD and primes antitumor immunity. Ye et al. showed that oncolytic NDV induces autophagy-dependent ICD in lung cancer cells (Ye et al., 2018). OVV synergizes with doxorubicin in inducing ICD in platinum-resistant ovarian cancer cells and increases survival in syngeneic and xenograft tumor models (Mistarz et al., 2021). In another study, Ma et al. demonstrated that wild-type adenovirus, semliki forest virus and OVV can induce various ICD while also stimulating antitumor immune responses (Ma et al., 2020).

**Oncolytic virus-mediated induction of apoptosis of tumor cells**

OVs are a novel therapeutic approach that works by activating immune function and inducing tumor cell apoptosis (Li et al., 2022a). As classical OVs studies rely heavily on their natural oncolysis, the discovery of tumor-selective virus-mediated apoptosis marks the appeal of an alternative cancer therapy in the form of OVs (Kalyanasundram et al., 2018). The replication ability of OVs in normal cells is low, while the virus can multiply specifically in tumor cells, which are lysed by the proliferation of the virus. OVs are described as naturally occurring or genetically engineered viruses that specifically replicate and induce apoptosis in cancer cells but not in normal cells (Fukuhara et al., 2016).

OV initiates targeted infection and induces tumor cell apoptosis while expressing therapeutic transgenes such as checkpoint inhibitors, cytokines, tumor antigens in the tumor (Rommelfanger et al., 2013). OVs immunotherapy and proteasome inhibition are two emerging targeted cancer therapies. It has been demonstrated that Bortezomib, a proteasome inhibitor, disrupts protein degradation in cells, leading to accumulation of unfolded proteins and induction of apoptosis (Aspirin et al., 2021). Wu et al. constructed an OV-like nanoplatform that degrades in an acidic tumor environment to release Poly IC and Zn2+. Importantly, released Poly IC has OV-like function and induces tumor cell apoptosis (Wu et al., 2022).

OVs can induce intracellular redistribution of Ras to promote apoptosis and progeny virus release (Garant et al., 2016). HSV, adenovirus and alphavirus mediate the induction of apoptosis for anti-prostate cancer (Lu et al., 2021). Oncolytic specificity of NDV is mediated by selectivity against apoptotic cells (Mansour et al., 2011). Discovery of tumor-selective virus-mediated apoptosis marks the emerge of an alternative cancer therapy using NDV strain AF2240 as an OV format (Kalyanasundram et al., 2018). Recently, an oncolytic measles virus encoding IL-12 treats colon cancer *in vivo* and *in vitro* to study its effect on colon cancer cell viability and apoptosis (Haghighi-Najafabadi et al., 2021). Turpin et al. illustrate the duality of ZIKA Virus-controlled apoptotic effects depending on whether it occurs (Turpin et al., 2022). Lal and Rajala developed a recombinant measles virus carrying BNiP3, a pro-apoptotic gene of human origin, as an oncolytic agent and demonstrated its ability to induce apoptosis in breast cancer cells *in vitro* (Lal and Rajala, 2018). Oncolytic goat herpesvirus 1 induces apoptosis in mesothelioma cell lines and synergizes with cisplatin as a new potential immunotherapy (Forte et al., 2021). IL-24 is an important cytokine that belongs to the family of activating caspases and promotes the repression of STAT3 when cells enter the apoptotic pathway. OVV carrying the IL-24 gene inhibits the growth of lung cancer by inducing apoptosis (Lv et al., 2016). Hypoxia- and telomerase-responsive oncolytic adenoviruses expressing secreted trimeric tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) trigger tumor-specific apoptosis and promote virus spread in TRAIL-resistant GBM (Oh et al., 2018). Furthermore, TRAIL-armed oncolytic poxvirus inhibits lung cancer cells by inducing apoptosis (Hu et al., 2018). NDV decreased mitochondrial membrane potential, suggesting an intrinsic pathway of apoptosis in oral cancer cells (Morla et al., 2019).

 An early study showed that oncolytic VSV induces apoptosis by modulating the PKR, Fas, and Daxx pathways (Gaddy and Lyles, 2007). Matrix protein mutants of VSV are promising oncolytic agents for cancer therapy. Lal and Rajala have developed a recombinant measles virus harboring BNiP3, a pro-apoptotic gene of human origin, which as an oncolytic agent, has been shown to induce apoptosis in breast cancer cells *in vitro* (Lal and Rajala, 2018). Recently, M51R and Delta-M51 matrix proteins of VSV induce apoptosis in colorectal cancer cells (Gray et al., 2019). Proto-parvovirus H-1 induces lytic infection and apoptosis *in vitro* but fails to improve survival *in vivo* (Lacroix et al., 2018).

**Oncolytic viruses-mediated cellular autophagy machinery in infected tumor cells**

 Upon infection, OV disrupts the autophagy machinery in infected tumor cells both *in vitro* and *in vivo.* The recent literature on targeting autophagy with either the autophagy inducers, such as rapamycin (Meng et al., 2013). Autophagy can crosstalk with OVs in cancer therapy (Jin et al., 2021) and induction of autophagy by OVs plays a dual role in GBM (Kamynina et al., 2021). Beclin-1 has been well characterized to play an important role in autophagy, the main catabolic pathway by which cells degrade macromolecules and damaged organelles. Importantly, Beclin1-armed OVV enhances the efficacy of first-line therapy with rituximab, cyclophosphamide, eirenicon, vindesine, and prednisolone against lymphoma *in vitro* and *in vivo* (Xie et al., 2021). Enhancement of therapeutic efficacy of OVV-armed with Beclin-1 was also seen in myeloma and leukemia (Lei et al., 2020). Oncolytic MRV has been demonstrated to induce autophagy in KRAS-mutated colorectal cancer (Jiffry et al., 2021).

 Interestingly, oncolytic paramyxoviruses have been found to induce autophagy and lead to tumor cell death rather than their survival. Oncolytic paramyxovirus induces autophagy as a discreet weapon in cancer therapy (Keshavarz et al., 2019). Deficiency in the inositol-requiring transmembrane kinase/endonuclease-1(IRE1α)-autophagy axis enhances the antitumor effect of oncolytic virus M1, a naturally occurring alphavirus. (Li et al., 2018). Furthermore, the class III phosphatidylinositol 3-kinase/Beclin-1 pathway plays a role in NDV-induced autophagy and virus production. Oncolytic NDV induces autophagy in U251 glioma cells to elevate virus replication (Meng et al., 2012). It was approved that pharmacological modulation of autophagy identified to enhance NDV-mediated oncolysis in drug-resistant lung cancer cells (Jiang et al., 2014). Autophagy participates in gastric adenocarcinoma cell death induced by recombinant NDV *in vitro* (Bu et al., 2015). Oncolytic NDV induces cell death of lung cancer spheroids and is further enhanced by pharmacological suppression of autophagy (Hu et al., 2015). Recently, the matrix protein of VSV has been shown that can cause autophagy-induced cell death in the breast cancer (Askari et al., 2021).

Mre11, the core of the Rad50/ Nbs1/Mre11 complex, is one of key DNA damage response proteins. Inhibition of Mre11 by oncolytic adenovirus is associated with autophagy and synergizes with ionizing radiation (Rajecki et al., 2009). Rodriguez-Rocha et al. demonstrate that adenovirus-induced autophagy is positively correlated with viral replication and oncolytic cell death, and that autophagy may generate nutrients that can be used to construct viral progeny particles (Rodriguez-Rocha et al., 2011). Suppression of autophagy increases the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells both *in vitro* and *in vivo* (Botta et al., 2012). Oncolytic adenovirus-induced autophagy exhibits a tumor-suppressive immunotherapy effect (Tazawa et al., 2013). Oncolytic adenoviruses and certain chemotherapeutic drugs induce autophagy and immunogenic cancer cell death. Temozolomide-containing oncolytic adenovirus induces autophagy and antitumor immune responses in cancer patients (Liikanen et al., 2013). A study by Cheng et al. evaluated that a unique combination of novel adenovirus-cycE (a novel E1b-deleted oncolytic adenovirus-cycE, in which Ad E1a gene is driven by the cyclin E promoter) with rapamycin, an autophagy inducer and first-line chemotherapy drug, suggesting that combination of autophagy inducer rapamycin and oncolytic adenovirus enhances antitumor effect of cancer cells (Cheng et al., 2013). Oncolytic adenoviruses, such as Delta-24-RGD, are replication-competent viruses that have been genetically engineered to induce selective cancer cell lysis. Oncolytic adenovirus-mediated autophagy has been shown to require the C-Jun N-terminal kinase (Klein et al., 2015). Oncolytic adenovirus Delta-24-RGD induces extensive glioma prototypical remodeling during autophagy (González-Morales et al., 2019). Furthermore, recombinant adenoviruses expressing apoptin inhibits the growth of MCF‑7 breast cancer cells and influences cell autophagy (Chen et al., 2019).

**Oncolytic viruses-mediated apoptosis, autophagy, syncytium formation in cancer cell lines in cancer cells**

 In addition to direct oncolysis, OV induces immunogenic cell death and elicits antitumor immunity. Ye et al. showed that the oncolytic NDV strain FMW (NDV/FMW) induces simultaneously apoptosis and autophagy in lung cancer cells (Ye et al., 2018). Oncolytic effect of NDV Hitcher B1 strain on cervical cancer cell proliferation is mediated by increased expression of cytochrome c, apoptosis and autophagy pathways (Mozaffari Nejad et al., 2020). Recombinant Chinese measles virus vaccine strain rMV-Hu191 inhibits the growth of human colorectal cancer by inducing autophagy and apoptosis via PI3K/Akt pathway (Zhang et al., 2021). RGD (Arg-Gly-Asp)-modified oncolytic adenovirus carrying shPKM2 (M2 isoform of pyruvate kinase) (OAd.R.shPKM2) exhibits potent cytotoxicity in pancreatic cancer by inhibiting autophagy and promoting apoptosis (Xu et al., 2017). A novel dual regulatory oncolytic adenovirus (Ad.wnt-E1A(△24bp)-TSLC1) targets Wnt signaling to efficiently inhibit cancer-like cell growth through apoptosis, autophagy and metastasis in a HCC model (Zhang et al., 2017). Oncolytic adenovirus AdΔΔ attenuates sensitivity to mitoxantrone-induced apoptosis via Bcl-2-dependent autophagy (Aguirre-Hernández et al., 2018). Furthermore, Araki et al. have demonstrated that oncolytic adenovirus OBP-702 promotes ICD with secretion of extracellular adenosine triphosphate and high-mobility group box protein B1 by regulating p53-induced apoptosis and autophagy. The OBP-702 significantly elevates the tumor infiltration of CD8+ T cells and the anti-tumor efficacy of PD-1 blockade in a subcutaneous PAN02 syngeneic tumor model (Araki et al., 2022). Japanese enveloped hemagglutination virus induces apoptosis and autophagy in human prostate cancer PC3 cells (Qian et al., 2018). Inactivated Sendai virus (ISV) was found to induce ROS-dependent apoptosis and autophagy in human prostate cancer cells (Qian et al., 2018). ISV strain Tianjin also induces apoptosis and autophagy through generation of reactive oxygen species in osteosarcoma MG-63 cells (Han et al., 2019).

Oncolytic ARV is not associated with human diseases, and preexisting immunity would not hinder its clinical application (Cai et al., 2019). Oncolytic ARV has been used in anti-cancer research (Benavente and Martínez-Costas, 2007; Chiu et al., 2018; Cai et al., 2019; Manocha et al., 2021; Li et al., 2022b) and is an emerging cancer virotherapy (Manocha et al., 2021). ARVs have several unique features that are different from MRV. They can induce syncytia to facilitate virus spread and distribution within a tumor. ARV was originally thought to act mainly through apoptosis (Shih et al., 2004; Chulu et al., 2007; Lin et al., 2011; Brown et al., 2018). The RhoA/ROCK1 pathway is known to regulate oncolytic ARV-mediated switch from autophagy to apoptosis (Lin et al., 2015). Several reports have suggested that ARV-induced apoptosis is through p53 and mitochondria-mediated pathway, and p53 is regulated by mitogen-activated protein kinases and protein kinase Cδ during ARV S1133-induced apoptosis (Chulu et al., 2007; Lin et al., 2009). Interestingly, the PI3-kinase/Akt/NF-κB and STAT3 signaling can be activated in the early stages of ARV infection which results in an inﬂammatory response and delayed apoptosis (Lin et al., 2010). Oncolytic ARV may combine with MRV due to their ability to evade pre-existing immunity. Oncolytic ARV σC protein is an apoptosis inducer which induces apoptosis (Shih et al., 2004), whereas p10 causes cytopathic effect (CPE) in mammalian and cancer cell lines (Liu et al., 2008). An earlier study suggested that p10 mediates syncytium formation through RhoA and Rac1-dependent signaling pathway (Liu et al., 2008). It was also reported that membrane-proximal basic residues, transmembrane glycine residues, and palmitoylation in the p10 protein are necessary for the formation of syncytium (Shmulevitz et al., 2003). More recently, it has been demonstrated that chitosan-based delivery of ARV p10 gene (ARV-p10 CH-NPs) is able to induce cell fusion in cultured melanoma cells, exhibiting a mild cytotoxic effect. Importantly, intratumor injection of ARV-p10 CH-NPs delayed tumor growth, without altering lymphoid populations in the spleen and tumor tissue (Robles-Planells et al., 2020). Recently, Jeon and Jung reported that the use of the murine leukemia virus (MLV)-based replication-competent retroviral (RCR) vector engineered to express the p10 fusion protein of Pulau virus in human cancer cell lines, inducing syncytium formation (Jeon and Jung, 2022). Thus, the RCR vector carrying p10 is a promising candidate for gene therapy for cancer. The nonstructural protein p17 of ARV is capable of modulating autophagy by regulating multiple signaling pathways, benefiting virus replication (Chi et al., 2013; Huang et al., 2015; Chiu et al., 2016; Huang et al., 2017; Chiu et al., 2018; Chiu et al., 2019; Huang et al., 2022b; Li et al., 2022b). ARV p17 also modulates cell cycle, viral protein synthesis, virus replication, and host cellular translation by regulating CDK/cyclin complexes, p53 and cyclin H interaction, polo-like kinase (PLK1), and the p53/PTEN/mTORC1 pathway (Chi et al., 2013; Huang et al., 2015; Chiu et al., 2016; Huang et al., 2017; Chiu et al., 2018; Chiu et al., 2019; Huang et al., 2022b; Li et al., 2022b). Since p17 induces autophagy by triggering PKR/eIF2α signaling pathways accompanied by suppression of Akt and mTORC1(Chi et al., 2013), it triggers the innate immune system and can mount a potent immune response against tumors (Cai et al., 2019; Chiu et al., 2019). Recent reports have revealed that p17 retards cell cycle of several cancer cell lines and reduces tumor size *in vivo* (Chiu et al., 2018), and suppresses angiogenesis by promoting DPP4 secretion (Manocha et al., 2021). More recently, it was demonstrated that ARV p17 is a HSP90 client protein that can regulate the formation of the HSP90/Cdc37 chaperone complex to increase its stabilization and enhance the synthesis and accumulation of viral structural proteins σA and σC in viral factories for virus assembly (Huang et al., 2022a; Huang et al., 2022b). The σA protein of ARV is known to be an activator of cellular energy, which enhances glycolysis and the TCA cycle and regulate cellular fatty acid metabolism to produce more ATP for virus replication in mammalian and human cancer cell lines (Chi et al., 2018; Hsu et al., 2022). Taken all findings together, oncolytic ARV is a promising candidate for cancer virotherapies. Collectively, OVs have advanced as promising anti-cancer immunotherapies by exploiting the apoptosis and autophagy pathways which underline the success of immunotherapy approaches.

**Clinical Trials**

OV is using as an anticancer agent in preclinical and clinical trials. Clinical trials have been conducted in the 1950s using wild-type and non-engineered *in vitro*-passaged virus strains and OV vaccine strains (Watanabe and Goshima, 2018). Using OVs to treat cancer is promising with clinical trial results (Malogolovkin et al., 2021). A variety of OVs, including genetically engineered and natural viruses, have shown promise in preclinical models and clinical studies. In 2005, China Food and Drug Administration (FDA) approved its first OV drug Oncorine (H101) and H101 based on human adenovirus 5 has been approved for human clinical trials (Shi and Zheng, 2009). OVV has also been systematically explored as an OV past 20 years. Of the three OVVs tested cancer patients, Pexa-Vec (JX-594) demonstrated clinical development of this OV, currently undergoing evaluation in a global Phase III clinical trial in patients with hepatocellular carcinoma (Guo et al. et al., 2019).

A phase I clinical trial with a second-generation oncolytic HSV expressing GM-CSF (Onco VEXGM-CSF) was conducted to determine the safety of the virus, seek evidence of biological activity, and determine dosage regimen for future studies. It was found that the phase I study of OncoVEXGM-CSF, a second-generation oncolytic HSV expressing GM-CSF in 2006. Onco VEXGM-CSF was well tolerated and could be administered safely using the multiple dose regimen described. Evidence for antitumor effects was seen. (Hu et al., 2006). This renewed interest in OVs led to the approval of the first OV, T-VEC based on HSV type 1, in 2015 by the US FDA and the European Medicines Agency (EMA) (Harrington et al., 2015). On October 27, 2015, the U.S. FDA officially approved T-VEC for the treatment of melanoma patients with injectable but unresectable lesions in the skin and lymph nodes. Imlygic® (T-VEC) commercialized by Amgen, Inc. thus became the first OV approved for cancer treatment in the United States (Pol et al., 2016). Cancer vaccines and OVs virotherapy are promising therapeutic strategies that have the potential to provide greater clinical benefit to patients with advanced cancer (Guo et al., 2019). OV agent T-VEC has been approved by the US FDA for the treatment of unresectable melanoma with limited visceral metastasis (Ripp et al., 2022).

 The use of cyclophosphamide as an immune modulator in phase I clinical trial can optimize oncolytic MRV being delivered to solid tumors (Roulstone et al., 2015). MRV displays tropism and replicates efficiently in tumor cells with the activated Ras pathway. This allows the application of MRV in immunotherapy, either alone or in combination with conventional and unconventional treatments, such as the synergistic cytotoxicity of MRV in combination with cisplatin-paclitaxel dual chemotherapy (Roulstone et al., 2013). MRV has been used in cancer immunotherapies under the name REOLYSIN®. This formulation of MRV has been tested in preclinical and phase I-III clinical trials across a broad range of cancer indications (Roulstone et al., 2013). Oncolytic HSV type 1 combination with lenalidomide has been applied to treat plasma cell neoplasms (Oku et al., 2021). OV is a new option emerging through systemic delivery of murine LIGHT (TNFSF14/CD258)-armed myxoma virus for the treatment of advanced syngeneic murine lung metastatic osteosarcoma (Christie et al., 2022). Oncolytic adenovirus Ad5/3-Δ24aCTLA4 stimulates T cells from cancer patients for clinical trials (Dias et al., 2012). Improving CAR T cell therapy for solid tumors by using OV-driven production of a bispecific T cell engager (BiTE) that could be further evaluated in clinical trials (Wing et al., 2018). Adenovirus Delta-24-RGD shows significant efficacy in phase I clinical trial of glioblastoma (GBM) (González-Morales et al., 2019). Mesothelin-redirected CAR T Cell therapy shows efficacy as antitumor agent in clinical trials (Watanabe et al., 2018). Clinical trials of combination therapies are underway, focusing on the association of immune checkpoint inhibitors with chemotherapy, with encouraging results, especially in the early stages with pembrolizumab and doxorubicin, anti-angiogenic agents and immune checkpoints inhibitors or synergy with OVs (Roulleaux Dugage et al., 2021). Teserpaturev/G47Δ (Delytact®) is a third-generation recombinant oncolytic HSV-1 developed by Daiichi Sankyo Corporation for the treatment of certain solid cancers. Teserpaturev/G47Δ has been approved in Japan for the treatment of malignant glioma and is currently in clinical trials for the treatment of prostate cancer (Phase II), malignant pleural mesothelioma (Phase I) and recurrent olfactory neuroblastoma (Phase I) development stage leading to the first approval for the treatment of malignant glioma (Frampton, 2022). Clinical trials in this mini review are showed in Table 1.

**Conclusion**

OVs destroy cancer cells by inducing multiple cell death pathways. These include apoptosis, necroptosis, autophagic cell death, and pyroptosis, each of which is a major form of death for specific OVs. OV-induced cancer cell death is mainly immunogenic and has the potential to elicit antitumor immune responses (Guo et al., 2014). The current progress of OVs in cancer treatment is the focus of this min-review. Their interaction with the immune system, ICD, apoptosis, and autophagy as well as new strategies in their virotherapy efficacy have been reviewed. OVs are antigen-agnostic cancer vaccines (Russell and Barber, 2018) and novel strategies for cancer treatment. OVs virotherapy are alternative promising therapeutic approaches against multiple chemo-resistant and radiation-resistant cancers (Fukuhara et al., 2016; Guo et al., 2017; Forte et al., 2021). Recombinant OVs are novel concepts to reduce the side effects of systemic cancer treatment while enhancing the oncolytic properties. An array of research efforts is ongoing in improving the virotherapy with OVs and these approaches hold great future promises to handle ever increasing issues of cancers.

**Author contributors**

YYW and HJL wrote the paper, HJL supervised the project. HJL, MSC, and MM revised

and edited the manuscript. All authors contributed to the article and approved the submitted version.

**Funding**

This work was financially supported by Ministry of Science and Technology of Taiwan (109-2313-B-005-006-MY3 & 111-2622-B-005-001), The iEGG and Animal Biotechnology Center from The Feature Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (111S0023A), National Chung Hsing University and Taichung Veterans General Hospital (TCVGH-NCHU1117608).

**Conflict of interest**

There is no conflict of interest for any authors in relation to this article.

Table 1. Clinical trials in this mini review

|  |  |  |  |
| --- | --- | --- | --- |
|  OV agent | Stage of development | Mode of action | Reference |
| Talimogene laherparepvec (T-VEC) | Approved by the U.S. FDA  | For the treatment of unresectable melanoma with limited visceral metastases | Ripp et al., 2022 |
| Imlygic® | Approved by the U.S. FDA | Talimogene laherparepvec (T-VEC, also known as OncoVEXGM-CSF) for the treatment of melanoma patients with injectable but unresectable lesions in the skin and lymph nodes.  | Pol et al., 2016 |
| T-VEC | Approved by the US FDA and the European Medicines Agency (EMA) | HSV modified to selectively grow in tumor cells and express the immunostimulatory transgenic granulocyte-macrophage colony-stimulating factor | Harrington et al., 2015 |
| Onco VEXGM-CSF | Phase I clinical trial | A second-generation oncolytic HSV expressing GM-CSF  | Hu et al., 2006 |
| Oncolytic MRV  | Phase I clinical trial | The use of cyclophosphamide as an immune modulator optimize MRV being delivered to solid tumors | Roulstone et al., 2015 |
| REOLYSIN® | Preclinical stage and phase I-III clinical trials | This formulation of the human reovirus in a broad range of cancer indications | Roulstone et al., 2013 |
| Oncolytic HSV type 1 | Treatment of plasma cell neoplasms | HSV type I combination with lenalidomide | Oku et al., 2021 |
| Myxoma virus | Therapeutic for later-stage syngeneic murine lung metastatic osteosarcoma | Options by systemic delivery of murine LIGHT (TNFSF14/CD258)-armed myxoma virus | Christie et al., 2022 |
| Oncolytic adenovirus Ad5/3-Δ24aCTLA4 | Testing the approach in clinical trials | Stimulation of T cells of cancer patients by oncolytic adenovirus Ad5/3-Δ24aCTLA4 | Dias et al., 2012 |
| CAR T cells therapy of solid tumors with oncolytic virus | Further evaluated in clinical trials | Driven production of a bispecific T-cell engager (BiTE) | Wing et al., 2018 |
| Adenovirus Delta-24-RGD | Phase I clinical trial | Adenovirus Delta-24-RGD has shown a remarkable efficacy for glioblastoma  | González-Morales et al., 2019 |
| Oncorine (H101) | Approved by China FDA | The first OV drug, the second gene therapy-based medicine, for treatment of advanced head and neck cancer | Shi and Zheng, 2009 |
| Pexa-Vec (JX-594) | Phase III clinical trial | OVVs tested cancer patients, Pexa-Vec (JX-594) demonstrated clinical development of this OV in patients with hepatocellular carcinoma  | Guo et al. et al., 2019 |
| Teserpaturev/G47Δ (Delytact®) | Clinical trials for the treatment of prostate cancer (Phase II), malignant pleural mesothelioma (Phase I), and recurrent olfactory neuroblastoma (Phase I) | Third-generation recombinant oncolytic herpes simplex virus type I developed by Daiichi Sankyo Corporation for the treatment of certain solid cancers | Frampton, 2022 |

**References**

Aguirre-Hernández, C., Maya-Pineda, H., Millán, J. S., Man, Y. K. S., Lu, Y. J., and Halldén, G. (2018). Sensitisation to mitoxantrone-induced apoptosis by the oncolytic adenovirus Ad∆∆ through Bcl-2-dependent attenuation of autophagy. *Oncogenesis, 7*(1), 6. doi:10.1038/s41389-017-0020-8

Ahmed, A., and Tait, S. W. G. (2020). Targeting immunogenic cell death in cancer. *Mol Oncol, 14*(12), 2994-3006. doi:10.1002/1878-0261.12851

Ang, L., Li, J., Dong, H., Wang, C., Huang, J., Li, M., et al. (2022). Chimeric oncolytic adenovirus armed chemokine rantes for treatment of breast cancer. *Bioengineering (Basel), 9*(8) , 342. doi:10.3390/bioengineering9080342

Angelova, A. L., Grekova, S. P., Heller, A., Kuhlmann, O., Soyka, E., Giese, T., et al. (2014). Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. *J Virol, 88*(10), 5263-5276. doi:10.1128/jvi.03688-13

Araki, H., Tazawa, H., Kanaya, N., Kajiwara, Y., Yamada, M., Hashimoto, M., et al. (2022). Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. *Mol Ther Oncolytics, 27*, 3-13. doi:10.1016/j.omto.2022.09.003

Askari, F. S., Mohebbi, A., Moradi, A., and Javid, N. (2021). The role of vesicular stomatitis virus matrix protein in autophagy in the breast cancer. *Asian Pac J Cancer Prev, 22*(1), 249-255. doi:10.31557/apjcp.2021.22.1.249

Aspirin, A. P., de Los Reyes, V. A., and Kim, Y. (2021). Polytherapeutic strategies with oncolytic virus-bortezomib and adjuvant NK cells in cancer treatment. *J R Soc Interface, 18*(174), 20200669. doi:10.1098/rsif.2020.0669

Bommareddy, P. K., Zloza, A., Rabkin, S. D., and Kaufman, H. L. (2019). Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. *Oncoimmunology, 8*(7), 1591875. doi:10.1080/2162402x.2019.1591875

Botta, G., Passaro, C., Libertini, S., Abagnale, A., Barbato, S., Maione, A. S., et al. (2012). Inhibition of autophagy enhances the effects of E1A-defective oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo. *Hum Gene Ther, 23*(6), 623-634. doi:10.1089/hum.2011.120

Brown, J. J., Short, S. P., Stencel-Baerenwald, J., Urbanek, K., Pruijssers, A. J., McAllister, N., et al. (2018). Reovirus-induced apoptosis in the intestine limits establishment of enteric infection. *J Virol, 92*(10), e02062-17. doi:10.1128/jvi.02062-17

Bu, X. F., Wang, M. B., Zhang, Z. J., Zhao, Y. H., Li, M., and Yan, Y. L. (2015). Autophagy is involved in recombinant Newcastle disease virus (rL-RVG)-induced cell death of stomach adenocarcinoma cells in vitro. *Int J Oncol, 47*(2), 679-689. doi:10.3892/ijo.2015.3039

Cai, R., Meng, G., Li, Y., Wang, W., Diao, Y., Zhao, S., et al. (2019). The oncolytic efficacy and safety of avian reovirus and its dynamic distribution in infected mice. *Exp Biol Med (Maywood), 244*(12), 983-991. doi:10.1177/1535370219861928

Chen, D., Huang, L., Zhou, H., and Zhang, Y. (2021). Combining IL-10 and oncolytic adenovirus demonstrates enhanced antitumor efficacy through CD8(+) T cells. *Front Immunol, 12*, 615089. doi:10.3389/fimmu.2021.615089

Chen, S., Li, Y. Q., Yin, X. Z., Li, S. Z., Zhu, Y. L., Fan, Y. Y., et al. (2019). Recombinant adenoviruses expressing apoptin suppress the growth of MCF‑7 breast cancer cells and affect cell autophagy. *Oncol Rep, 41*(5), 2818-2832. doi:10.3892/or.2019.7077

Chen, T., Ding, X., Liao, Q., Gao, N., Chen, Y., Zhao, C., et al. (2021). IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy. *J Immunother Cancer, 9*(1), e001647. doi:10.1136/jitc-2020-001647

Cheng, P. H., Lian, S., Zhao, R., Rao, X. M., McMasters, K. M., and Zhou, H. S. (2013). Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells. *Virol J, 10*, 293. doi:10.1186/1743-422x-10-293

Chi, P. I., Huang, W. R., Chiu, H. C., Li, J. Y., Nielsen, B. L., and Liu, H. J. (2018). Avian reovirus σA-modulated suppression of lactate dehydrogenase and upregulation of glutaminolysis and the mTOC1/eIF4E/HIF-1α pathway to enhance glycolysis and the TCA cycle for virus replication. *Cell Microbiol, 20*(12), e12946. doi:10.1111/cmi.12946

Chi, P. I., Huang, W. R., Lai, I. H., Cheng, C. Y., and Liu, H. J. (2013). The p17 nonstructural protein of avian reovirus triggers autophagy enhancing virus replication via activation of phosphatase and tensin deleted on chromosome 10 (PTEN) and AMP-activated protein kinase (AMPK), as well as dsRNA-dependent protein kinase (PKR)/eIF2α signaling pathways. *J Biol Chem, 288*(5), 3571-3584. doi:10.1074/jbc.M112.390245

Chiu, H. C., Huang, W. R., Liao, T. L., Chi, P. I., Nielsen, B. L., Liu, J. H., and Liu, H. J. (2018). Mechanistic insights into avian reovirus p17-modulated suppression of cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H interaction. *J Biol Chem, 293*(32), 12542-12562. doi:10.1074/jbc.RA118.002341

Chiu, H. C., Huang, W. R., Liao, T. L., Wu, H. Y., Munir, M., Shih, W. L., and Liu, H. J. (2016). Suppression of vimentin phosphorylation by the avian reovirus p17 through inhibition of CDK1 and Plk1 impacting the G2/M phase of the cell cycle. *PLoS One, 11*(9), e0162356. doi:10.1371/journal.pone.0162356

Chiu, H. C., Huang, W. R., Wang, Y. Y., Li, J. Y., Liao, T. L., Nielsen, B. L., and Liu, H. J. (2019). Heterogeneous Nuclear Ribonucleoprotein A1 and Lamin A/C Modulate Nucleocytoplasmic Shuttling of Avian Reovirus p17. *J Virol, 93*(20) , e00851-19. doi:10.1128/jvi.00851-19

Christie, J. D., Appel, N., Canter, H., Achi, J. G., Elliott, N. M., de Matos, A. L., et al. (2021). Systemic delivery of TNF-armed myxoma virus plus immune checkpoint inhibitor eliminates lung metastatic mouse osteosarcoma. *Mol Ther Oncolytics, 22*, 539-554. doi:10.1016/j.omto.2021.07.014

Christie, J. D., Appel, N., Zhang, L., Lowe, K., Kilbourne, J., Daggett-Vondras, J., et al. (2022). Systemic delivery of mLIGHT-armed myxoma virus is therapeutic for later-stage syngeneic murine lung metastatic osteosarcoma. *Cancers (Basel), 14*(2) , 337. doi:10.3390/cancers14020337

Chulu, J. L., Lee, L. H., Lee, Y. C., Liao, S. H., Lin, F. L., Shih, W. L., and Liu, H. J. (2007). Apoptosis induction by avian reovirus through p53 and mitochondria-mediated pathway. *Biochem Biophys Res Commun, 356*(3), 529-535. doi:10.1016/j.bbrc.2007.02.164

Di Somma, S., Iannuzzi, C. A., Passaro, C., Forte, I. M., Iannone, R., Gigantino, V., et al. (2019). The oncolytic virus dl922-947 triggers immunogenic cell death in mesothelioma and reduces xenograft growth. *Front Oncol, 9*, 564. doi:10.3389/fonc.2019.00564

Dias, J. D., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, A., Guse, K., et al. (2012). Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. *Gene Ther, 19*(10), 988-998. doi:10.1038/gt.2011.176

Draganov, D. D., Santidrian, A. F., Minev, I., Nguyen, D., Kilinc, M. O., Petrov, I., et al. (2019). Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers. *J Transl Med, 17*(1), 100. doi:10.1186/s12967-019-1829-z

Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., et al. (2020). Oncolytic virus-derived type I interferon restricts CAR T cell therapy. *Nat Commun, 11*(1), 3187. doi:10.1038/s41467-020-17011-z

Evgin, L., Kottke, T., Tonne, J., Thompson, J., Huff, A. L., van Vloten, J., et al. (2022). Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. *Sci Transl Med, 14*(640), eabn2231. doi:10.1126/scitranslmed.abn2231

Feng, M., Zhao, Z., Yang, M., Ji, J., and Zhu, D. (2021). T-cell-based immunotherapy in colorectal cancer. *Cancer Lett, 498*, 201-209. doi:10.1016/j.canlet.2020.10.040

Forte, I. M., Indovina, P., Montagnaro, S., Costa, A., Iannuzzi, C. A., Capone, F., et al. (2021). The oncolytic caprine herpesvirus 1 (CpHV-1) induces apoptosis and synergizes with cisplatin in mesothelioma cell lines: A new potential virotherapy approach. *Viruses, 13*(12), 2458. doi:10.3390/v13122458

Frampton, J. E. (2022). Teserpaturev/G47Δ: First Approval. *BioDrugs, 36*(5), 667-672. doi:10.1007/s40259-022-00553-7

Frumence, E., Roche, M., Krejbich-Trotot, P., El-Kalamouni, C., Nativel, B., Rondeau, P., et al. (2016). The South Pacific epidemic strain of Zika virus replicates efficiently in human epithelial A549 cells leading to IFN-β production and apoptosis induction. *Virology, 493*, 217-226. doi:10.1016/j.virol.2016.03.006

Fu, X., Rivera, A., Tao, L., and Zhang, X. (2015). An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites. *Oncotarget, 6*(2), 902-914. doi:10.18632/oncotarget.2817

Fukuhara, H., Ino, Y., and Todo, T. (2016). Oncolytic virus therapy: A new era of cancer treatment at dawn. *Cancer Sci, 107*(10), 1373-1379. doi:10.1111/cas.13027

Gaddy, D. F., and Lyles, D. S. (2007). Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. *J Virol, 81*(6), 2792-2804. doi:10.1128/jvi.01760-06

Garant, K. A., Shmulevitz, M., Pan, L., Daigle, R. M., Ahn, D. G., Gujar, S. A., and Lee, P. W. (2016). Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. *Oncogene, 35*(6), 771-782. doi:10.1038/onc.2015.136

Gebremeskel, S., Nelson, A., Walker, B., Oliphant, T., Lobert, L., Mahoney, D., and Johnston, B. (2021). Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis. *J Immunother Cancer, 9*(3), e002096. doi:10.1136/jitc-2020-002096

Glorioso, J. C., Cohen, J. B., Goins, W. F., Hall, B., Jackson, J. W., Kohanbash, G., et al. (2021). Oncolytic HSV vectors and anti-tumor immunity. *Curr Issues Mol Biol, 41*, 381-468. doi:10.21775/cimb.041.381

González-Morales, A., Zabaleta, A., García-Moure, M., Alonso, M. M., Fernández-Irigoyen, J., and Santamaría, E. (2019). Oncolytic adenovirus Delta-24-RGD induces a widespread glioma proteotype remodeling during autophagy. *J Proteomics, 194*, 168-178. doi:10.1016/j.jprot.2018.11.020

Gray, Z., Tabarraei, A., Moradi, A., and Kalani, M. R. (2019). M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells. *Mol Biol Rep, 46*(3), 3371-3379. doi:10.1007/s11033-019-04799-3

Guedan, S., and Alemany, R. (2018). CAR-T cells and oncolytic viruses: Joining forces to overcome the solid tumor challenge. *Front Immunol, 9*, 2460. doi:10.3389/fimmu.2018.02460

Guo, Z. S., Liu, Z., and Bartlett, D. L. (2014). Oncolytic immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. *Front Oncol, 4*, 74. doi:10.3389/fonc.2014.00074

Guo, Z. S., Liu, Z., Kowalsky, S., Feist, M., Kalinski, P., Lu, B., et al. (2017). Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. *Front Immunol, 8*, 555. doi:10.3389/fimmu.2017.00555

Guo, Z. S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., et al. (2019). Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. *J Immunother Cancer, 7*(1), 6. doi:10.1186/s40425-018-0495-7

Haghighi-Najafabadi, N., Roohvand, F., Shams Nosrati, M. S., Teimoori-Toolabi, L., and Azadmanesh, K. (2021). Oncolytic herpes simplex virus type-1 expressing IL-12 efficiently replicates and kills human colorectal cancer cells. *Microb Pathog, 160*, 105164. doi:10.1016/j.micpath.2021.105164

Han, Z., Li, Q., Sun, S., Zhao, W., and Shi, L. (2019). Inactivated Sendai virus strain Tianjin induces apoptosis and autophagy through reactive oxygen species production in osteosarcoma MG-63 cells. *J Cell Physiol, 234*(4), 4179-4190. doi:10.1002/jcp.27176

Harrington, K. J., Puzanov, I., Hecht, J. R., Hodi, F. S., Szabo, Z., Murugappan, S., and Kaufman, H. L. (2015). Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. *Expert Rev Anticancer Ther, 15*(12), 1389-1403. doi:10.1586/14737140.2015.1115725

Heidbuechel, J. P. W., and Engeland, C. E. (2021). Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. *J Hematol Oncol, 14*(1), 63. doi:10.1186/s13045-021-01075-5

Hsu, C. Y., Chen, Y. H., Huang, W. R., Huang, J. W., Chen, I. C., Chang, Y. K., et al. (2022). Oncolytic avian reovirus σA-modulated fatty acid metabolism through the PSMB6/Akt/SREBP1/acetyl-CoA carboxylase pathway to increase energy production for virus replication. *Vet Microbiol, 273*, 109545. doi:10.1016/j.vetmic.2022.109545

Hu, J., Wang, H., Gu, J., Liu, X., and Zhou, X. (2018). Trail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis. *Acta Biochim Biophys Sin (Shanghai), 50*(10), 1018-1027. doi:10.1093/abbs/gmy096

Hu, J. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. *Clin Cancer Res, 12*(22), 6737-6747. doi:10.1158/1078-0432.Ccr-06-0759

Hu, L., Sun, S., Wang, T., Li, Y., Jiang, K., Lin, G., et al. (2015). Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy. *Am J Cancer Res, 5*(12), 3612-3623.

Huang, J., Zheng, M., Zhang, Z., Tang, X., Chen, Y., Peng, A., et al. (2021). Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. *Cancer Immunol Immunother, 70*(9), 2453-2465. doi:10.1007/s00262-021-02856-0

Huang, W. R., Chi, P. I., Chiu, H. C., Hsu, J. L., Nielsen, B. L., Liao, T. L., and Liu, H. J. (2017). Avian reovirus p17 and σA act cooperatively to downregulate Akt by suppressing mTORC2 and CDK2/cyclin A2 and upregulating proteasome PSMB6. *Sci Rep, 7*(1), 5226. doi:10.1038/s41598-017-05510-x

Huang, W. R., Chiu, H. C., Liao, T. L., Chuang, K. P., Shih, W. L., and Liu, H. J. (2015). Avian reovirus protein p17 functions as a nucleoporin Tpr suppressor leading to activation of p53, p21 and PTEN and inactivation of PI3K/AKT/mTOR and ERK signaling pathways. *PLoS One, 10*(8), e0133699. doi:10.1371/journal.pone.0133699

Huang, W. R., Li, J. Y., Liao, T. L., Yeh, C. M., Wang, C. Y., Wen, H. W., et al. (2022a). Molecular chaperone TRiC governs avian reovirus replication by protecting outer-capsid protein σC and inner core protein σA and non-structural protein σNS from ubiquitin- proteasome degradation. *Vet Microbiol, 264*, 109277. doi:10.1016/j.vetmic.2021.109277

Huang, W. R., Li, J. Y., Wu, Y. Y., Liao, T. L., Nielsen, B. L., and Liu, H. J. (2022b). p17-modulated Hsp90/Cdc37 complex governs oncolytic avian reovirus replication by chaperoning p17, which promotes viral protein synthesis and accumulation of viral proteins σC and σA in viral factories. *J Virol, 96*(6), e0007422. doi:10.1128/jvi.00074-22

Inoue, H., and Tani, K. (2014). Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. *Cell Death Differ, 21*(1), 39-49. doi:10.1038/cdd.2013.84

Inoue, T., Byrne, T., Inoue, M., Tait, M. E., Wall, P., Wang, A., et al. (2021). Oncolytic vaccinia virus gene modification and cytokine expression effects on tumor infection, immune response, and killing. *Mol Cancer Ther, 20*(8), 1481-1494. doi:10.1158/1535-7163.Mct-20-0863

Jiang, K., Li, Y., Zhu, Q., Xu, J., Wang, Y., Deng, W., et al. (2014). Pharmacological modulation of autophagy enhances Newcastle disease virus-mediated oncolysis in drug-resistant lung cancer cells. *BMC Cancer, 14*, 551. doi:10.1186/1471-2407-14-551

Jiffry, J., Thavornwatanayong, T., Rao, D., Fogel, E. J., Saytoo, D., Nahata, R., et al. (2021). Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer. *Clin Cancer Res, 27*(3), 865-876. doi:10.1158/1078-0432.Ccr-20-2385

Jin, J., Wang, R., Yang, J., Hu, H., Wang, D., Cai, L., et al. (2022). Bispecific antibody expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells. *Hum Gene Ther, 33*(11-12), 649-663. doi:10.1089/hum.2021.277

Jin, K. T., Tao, X. H., Fan, Y. B., and Wang, S. B. (2021). Crosstalk between oncolytic viruses and autophagy in cancer therapy. *Biomed Pharmacother, 134*, 110932. doi:10.1016/j.biopha.2020.110932

Kalus, P., De Munck, J., Vanbellingen, S., Carreer, L., Laeremans, T., Broos, K., et al. (2022). Oncolytic herpes simplex virus type 1 induces immunogenic cell death resulting in maturation of BDCA-1(+) myeloid dendritic cells. *Int J Mol Sci, 23*(9). doi:10.3390/ijms23094865

Kalyanasundram, J., Hamid, A., Yusoff, K., and Chia, S. L. (2018). Newcastle disease virus strain AF2240 as an oncolytic virus: A review. *Acta Trop, 183*, 126-133. doi:10.1016/j.actatropica.2018.04.007

Kamynina, M., Tskhovrebova, S., Fares, J., Timashev, P., Laevskaya, A., and Ulasov, I. (2021). Oncolytic virus-induced autophagy in glioblastoma. *Cancers (Basel), 13*(14), 3482. doi:10.3390/cancers13143482

Kanaya, N., Kuroda, S., Kakiuchi, Y., Kumon, K., Tsumura, T., Hashimoto, M., et al. (2020). Immune modulation by telomerase-specific oncolytic adenovirus synergistically enhances antitumor efficacy with anti-PD1 antibody. *Mol Ther, 28*(3), 794-804. doi:10.1016/j.ymthe.2020.01.003

Keshavarz, M., Solaymani-Mohammadi, F., Miri, S. M., and Ghaemi, A. (2019). Oncolytic paramyxoviruses-induced autophagy; a prudent weapon for cancer therapy. *J Biomed Sci, 26*(1), 48. doi:10.1186/s12929-019-0542-9

Kim, D. S., Dastidar, H., Zhang, C., Zemp, F. J., Lau, K., Ernst, M., et al. (2017). Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. *Nat Commun, 8*(1), 344. doi:10.1038/s41467-017-00324-x

Kim, K. J., Moon, D., Kong, S. J., Lee, Y. S., Yoo, Y., Kim, S., et al. (2021). Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1. *Gene Ther, 28*(3-4), 186-198. doi:10.1038/s41434-020-00205-x

Klein, S. R., Piya, S., Lu, Z., Xia, Y., Alonso, M. M., White, E. J., et al. (2015). C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy. *Oncogene, 34*(41), 5295-5301. doi:10.1038/onc.2014.452

Klose, C., Berchtold, S., Schmidt, M., Beil, J., Smirnow, I., Venturelli, S., et al (2019). Biological treatment of pediatric sarcomas by combined virotherapy and NK cell therapy. *BMC Cancer, 19*(1), 1172. doi:10.1186/s12885-019-6387-5

Kontermann, R. E., Ungerechts, G., and Nettelbeck, D. M. (2021). Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics. *MAbs, 13*(1), 1982447. doi:10.1080/19420862.2021.1982447

Lacroix, J., Kis, Z., Josupeit, R., Schlund, F., Stroh-Dege, A., Frank-Stöhr, M., et al. (2018). Preclinical testing of an oncolytic parvovirus in ewing sarcoma: Protoparvovirus H-1 induces apoptosis and lytic infection in vitro but fails to improve survival in Vivo. *Viruses, 10*(6) , 302. doi:10.3390/v10060302

Lal, G., and Rajala, M. S. (2018). Combination of oncolytic measles virus armed with BNiP3, a pro-apoptotic gene and paclitaxel induces breast cancer cell death. *Front Oncol, 8*, 676. doi:10.3389/fonc.2018.00676

Lei, W., Wang, S., Xu, N., Chen, Y., Wu, G., Zhang, A., et al. (2020). Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma. *Biomed Pharmacother, 125*, 110030. doi:10.1016/j.biopha.2020.110030

Li, J., Meng, Q., Zhou, X., Zhao, H., Wang, K., Niu, H., and Wang, Y. (2022a). Gospel of malignant Glioma: Oncolytic virus therapy. *Gene, 818*, 146217. doi:10.1016/j.gene.2022.146217

Li, J. Y., Huang, W. R., Liao, T. L., Nielsen, B. L., and Liu, H. J. (2022b). Oncolytic avian reovirus p17-modulated inhibition of mTORC1 by enhancement of endogenous mTORC1 inhibitors binding to mTORC1 to disrupt its assembly and accumulation on lysosomes. *J Virol, 96*(17), e0083622. doi:10.1128/jvi.00836-22

Li, K., Hu, C., Xing, F., Gao, M., Liang, J., Xiao, X., et al. (2018). Deficiency of the IRE1α-autophagy axis enhances the antitumor effects of the oncolytic virus M1. *J Virol, 92*(6), e01331-17. doi:10.1128/jvi.01331-17

Liikanen, I., Ahtiainen, L., Hirvinen, M. L., Bramante, S., Cerullo, V., Nokisalmi, P., et al. (2013). Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. *Mol Ther, 21*(6), 1212-1223. doi:10.1038/mt.2013.51

Lin, P. Y., Chang, C. D., Chen, Y. C., and Shih, W. L. (2015). RhoA/ROCK1 regulates Avian Reovirus S1133-induced switch from autophagy to apoptosis. *BMC Vet Res, 11*, 103. doi:10.1186/s12917-015-0417-6

Lin, P. Y., Lee, J. W., Liao, M. H., Hsu, H. Y., Chiu, S. J., Liu, H. J., and Shih, W. L. (2009). Modulation of p53 by mitogen-activated protein kinase pathways and protein kinase C delta during avian reovirus S1133-induced apoptosis. *Virology, 385*(2), 323-334. doi:10.1016/j.virol.2008.12.028

Lin, P. Y., Liu, H. J., Chang, C. D., Chang, C. I., Hsu, J. L., Liao, M. H., et al. (2011). Avian reovirus S1133-induced DNA damage signaling and subsequent apoptosis in cultured cells and in chickens. *Arch Virol, 156*(11), 1917-1929. doi:10.1007/s00705-011-1063-3

Lin, P. Y., Liu, H. J., Liao, M. H., Chang, C. D., Chang, C. I., Cheng, H. L., et al. (2010). Activation of PI 3-kinase/Akt/NF-kappaB and Stat3 signaling by avian reovirus S1133 in the early stages of infection results in an inflammatory response and delayed apoptosis. *Virology, 400*(1), 104-114. doi:10.1016/j.virol.2010.01.024

Liu, H. J., Lin, P. Y., Wang, L. R., Hsu, H. Y., Liao, M. H., and Shih, W. L. (2008). Activation of small GTPases RhoA and Rac1 is required for avian reovirus p10-induced syncytium formation. *Mol Cells, 26*(4), 396-403.

Lorence, R. M., Rood, P. A., and Kelley, K. W. (1988). Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. *J Natl Cancer Inst, 80*(16), 1305-1312. doi:10.1093/jnci/80.16.1305

Lu, M., Wei, F., Ma, S., Xu, Z., Wang, J., Yang, C., and Mao, L. (2021). Oncolytic virus as a novel modality for the treatment of prostate cancer. *Discov Med, 32*(167), 133-139.

Lv, C., Su, Q., Liang, Y., Hu, J., and Yuan, S. (2016). Oncolytic vaccine virus harbouring the IL-24 gene suppresses the growth of lung cancer by inducing apoptosis. *Biochem Biophys Res Commun, 476*(1), 21-28. doi:10.1016/j.bbrc.2016.05.088

Ma, J., Ramachandran, M., Jin, C., Quijano-Rubio, C., Martikainen, M., Yu, D., and Essand, M. (2020). Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer. *Cell Death Dis, 11*(1), 48. doi:10.1038/s41419-020-2236-3

Ma, R., Lu, T., Li, Z., Teng, K. Y., Mansour, A. G., Yu, M., et al. (2021). An oncolytic virus expressing IL15/IL15Rα combined with Off-the-Shelf EGFR-CAR NK cells targets glioblastoma. *Cancer Res, 81*(13), 3635-3648. doi:10.1158/0008-5472.Can-21-0035

Ma, W., He, H., and Wang, H. (2018). Oncolytic herpes simplex virus and immunotherapy. *BMC Immunol, 19*(1), 40. doi:10.1186/s12865-018-0281-9

Mahmoud, M. H., Badr, G., Badr, B. M., Kassem, A. U., and Mohamed, M. S. (2015). Elevated IFN-alpha/beta levels in a streptozotocin-induced type I diabetic mouse model promote oxidative stress and mediate depletion of spleen-homing CD8+ T cells by apoptosis through impaired CCL21/CCR7 axis and IL-7/CD127 signaling. *Cell Signal, 27*(10), 2110-2119. doi:10.1016/j.cellsig.2015.07.005

Malogolovkin, A., Gasanov, N., Egorov, A., Weener, M., Ivanov, R., and Karabelsky, A. (2021). Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes. *Viruses, 13*(7), 1271. doi:10.3390/v13071271

Manocha, E., Bugatti, A., Belleri, M., Zani, A., Marsico, S., Caccuri, F., et al. (2021). Avian reovirus P17 suppresses angiogenesis by promoting DPP4 secretion. *Cells, 10*(2), 259. doi:10.3390/cells10020259

Manocha, E., Caruso, A., and Caccuri, F. (2021). Viral proteins as emerging cancer therapeutics. *Cancers (Basel), 13*(9), 2199. doi:10.3390/cancers13092199

Mansour, M., Palese, P., and Zamarin, D. (2011). Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. *J Virol, 85*(12), 6015-6023. doi:10.1128/jvi.01537-10

Mardi, A., Shirokova, A. V., Mohammed, R. N., Keshavarz, A., Zekiy, A. O., Thangavelu, L., et al. (2022). Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. *Cancer Cell Int, 22*(1), 168. doi:10.1186/s12935-022-02585-z

Meng, C., Zhou, Z., Jiang, K., Yu, S., Jia, L., Wu, Y., et al. (2012). Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. *Arch Virol, 157*(6), 1011-1018. doi:10.1007/s00705-012-1270-6

Meng, S., Xu, J., Wu, Y., and Ding, C. (2013). Targeting autophagy to enhance oncolytic virus-based cancer therapy. *Expert Opin Biol Ther, 13*(6), 863-873. doi:10.1517/14712598.2013.774365

Mistarz, A., Graczyk, M., Winkler, M., Singh, P. K., Cortes, E., Miliotto, A., et al. (2021). Induction of cell death in ovarian cancer cells by doxorubicin and oncolytic vaccinia virus is associated with CREB3L1 activation. *Mol Ther Oncolytics, 23*, 38-50. doi:10.1016/j.omto.2021.04.014

Mondal, M., Guo, J., He, P., and Zhou, D. (2020). Recent advances of oncolytic virus in cancer therapy. *Hum Vaccin Immunother, 16*(10), 2389-2402. doi:10.1080/21645515.2020.1723363

Moralès, O., Richard, A., Martin, N., Mrizak, D., Sénéchal, M., Miroux, C., et al. (2012). Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus. *PLoS One, 7*(2), e32197. doi:10.1371/journal.pone.0032197

Moreno, R. (2021). Mesenchymal stem cells and oncolytic viruses: joining forces against cancer. *J Immunother Cancer, 9*(2), e001684. doi:10.1136/jitc-2020-001684

Moreno, R., Fajardo, C. A., Farrera-Sal, M., Perisé-Barrios, A. J., Morales-Molina, A., Al-Zaher, A. A., et al. (2019). Enhanced antitumor efficacy of oncolytic adenovirus-loaded menstrual blood-derived mesenchymal stem cells in combination with peripheral blood mononuclear cells. *Mol Cancer Ther, 18*(1), 127-138. doi:10.1158/1535-7163.Mct-18-0431

Morla, S., Kumar, A., and Kumar, S. (2019). Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: A probable role of β-catenin and matrix metalloproteinase-7. *Sci Rep, 9*(1), 10882. doi:10.1038/s41598-019-47244-y

Morrish, E., Brumatti, G., and Silke, J. (2020). Future therapeutic directions for Smac-Mimetics. *Cells, 9*(2), 406. doi:10.3390/cells9020406

Mozaffari Nejad, A. S., Fotouhi, F., Mehrbod, P., Keshavarz, M., Alikhani, M. Y., and Ghaemi, A. (2020). Oncolytic effects of Hitchner B1 strain of newcastle disease virus against cervical cancer cell proliferation is mediated by the increased expression of cytochrome C, autophagy and apoptotic pathways. *Microb Pathog, 147*, 104438. doi:10.1016/j.micpath.2020.104438

Nair, S., Mazzoccoli, L., Jash, A., Govero, J., Bais, S. S., Hu, T., et al. (2021). Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. *JCI Insight, 6*(1), e144619. doi:10.1172/jci.insight.144619

Nguyen, T. T., Shin, D. H., Sohoni, S., Singh, S. K., Rivera-Molina, Y., Jiang, H., et al. (2022). Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry. *J Immunother Cancer, 10*(7), e004935. doi:10.1136/jitc-2022-004935

Oh, E., Hong, J., Kwon, O. J., and Yun, C. O. (2018). A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma. *Sci Rep, 8*(1), 1420. doi:10.1038/s41598-018-19300-6

Oku, M., Ishino, R., Uchida, S., Imataki, O., Sugimoto, N., Todo, T., and Kadowaki, N. (2021). Oncolytic herpes simplex virus type 1 (HSV-1) in combination with lenalidomide for plasma cell neoplasms. *Br J Haematol, 192*(2), 343-353. doi:10.1111/bjh.17173

Packiriswamy, N., Upreti, D., Zhou, Y., Khan, R., Miller, A., Diaz, R. M., et al. (2020). Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. *Leukemia, 34*(12), 3310-3322. doi:10.1038/s41375-020-0828-7

Pol, J., Kroemer, G., and Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy. *Oncoimmunology, 5*(1), e1115641. doi:10.1080/2162402x.2015.1115641

Qian, M., Tan, H. M., Yu, N., Wang, T., and Zhang, Q. (2018). Inactivated sendai virus induces ROS-dependent apoptosis and autophagy in human prostate cancer cells. *Biomed Environ Sci, 31*(4), 280-289. doi:10.3967/bes2018.036

Rajecki, M., af Hällström, T., Hakkarainen, T., Nokisalmi, P., Hautaniemi, S., Nieminen, A. I., et al. (2009). Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation. *Int J Cancer, 125*(10), 2441-2449. doi:10.1002/ijc.24608

Ripp, J., Hentzen, S., and Saeed, A. (2022). Oncolytic viruses as an adjunct to immune checkpoint inhibition. *Front Biosci (Landmark Ed), 27*(5), 151. doi:10.31083/j.fbl2705151

Rivadeneira, D. B., DePeaux, K., Wang, Y., Kulkarni, A., Tabib, T., Menk, A. V., et al. (2019). Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. *Immunity, 51*(3), 548-560.e544. doi:10.1016/j.immuni.2019.07.003

Rodriguez-Rocha, H., Gomez-Gutierrez, J. G., Garcia-Garcia, A., Rao, X. M., Chen, L., McMasters, K. M., and Zhou, H. S. (2011). Adenoviruses induce autophagy to promote virus replication and oncolysis. *Virology, 416*(1-2), 9-15. doi:10.1016/j.virol.2011.04.017

Rommelfanger, D. M., Compte, M., Grau, M. C., Diaz, R. M., Ilett, E., Alvarez-Vallina, L., et al. (2013). The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. *Mol Ther, 21*(2), 348-357. doi:10.1038/mt.2012.204

Roulleaux Dugage, M., Nassif, E. F., Italiano, A., & Bahleda, R. (2021). Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and histotype tailored review. *Front Immunol, 12*, 775761. doi:10.3389/fimmu.2021.775761

Roulstone, V., Khan, K., Pandha, H. S., Rudman, S., Coffey, M., Gill, G. M., et al. (2015). Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. *Clin Cancer Res, 21*(6), 1305-1312. doi:10.1158/1078-0432.Ccr-14-1770

Roulstone, V., Twigger, K., Zaidi, S., Pencavel, T., Kyula, J. N., White, C., et al. (2013). Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy. *Gene Ther, 20*(5), 521-528. doi:10.1038/gt.2012.68

Russell, S. J., and Barber, G. N. (2018). Oncolytic viruses as antigen-agnostic cancer vaccines. *Cancer Cell, 33*(4), 599-605. doi:10.1016/j.ccell.2018.03.011

Saha, D., Wakimoto, H., and Rabkin, S. D. (2016). Oncolytic herpes simplex virus interactions with the host immune system. *Curr Opin Virol, 21*, 26-34. doi:10.1016/j.coviro.2016.07.007

Schiller, M., Parcina, M., Heyder, P., Foermer, S., Ostrop, J., Leo, A., et al. (2012). Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. *J Immunol, 189*(4), 1747-1756. doi:10.4049/jimmunol.1100631

Shao, X., Wang, X., Guo, X., Jiang, K., Ye, T., Chen, J., et al. (2019). STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells. *Front Oncol, 9*, 436. doi:10.3389/fonc.2019.00436

Shi, J., and Zheng, D. (2009). An update on gene therapy in China. *Curr Opin Mol Ther, 11*(5), 547-553.

Shih, W. L., Hsu, H. W., Liao, M. H., Lee, L. H., and Liu, H. J. (2004). Avian reovirus sigmaC protein induces apoptosis in cultured cells. *Virology, 321*(1), 65-74. doi:10.1016/j.virol.2003.12.004

Sobhanimonfared, F., Bamdad, T., Sadigh, Z. A., and Choobin, H. (2020). Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy. *Microb Pathog, 140*, 103957. doi:10.1016/j.micpath.2019.103957

Takasu, A., Masui, A., Hamada, M., Imai, T., Iwai, S., and Yura, Y. (2016). Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells. *Cancer Gene Ther, 23*(4), 107-113. doi:10.1038/cgt.2016.8

Tazawa, H., Kagawa, S., and Fujiwara, T. (2013). Oncolytic adenovirus-induced autophagy: tumor-suppressive effect and molecular basis. *Acta Med Okayama, 67*(6), 333-342. doi:10.18926/amo/52006

Turpin, J., El Safadi, D., Lebeau, G., Krejbich, M., Chatelain, C., Desprès, P., et al. (2022). Apoptosis during ZIKA Virus Infection: Too Soon or Too Late? *Int J Mol Sci, 23*(3), 1287. doi:10.3390/ijms23031287

van Vloten, J. P., Workenhe, S. T., Wootton, S. K., Mossman, K. L., and Bridle, B. W. (2018). Critical interactions between immunogenic cancer cell death, oncolytic viruses, and the immune system define the rational design of combination immunotherapies. *J Immunol, 200*(2), 450-458. doi:10.4049/jimmunol.1701021

Wang, G., Kang, X., Chen, K. S., Jehng, T., Jones, L., Chen, J., et al. (2020). An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. *Nat Commun, 11*(1), 1395. doi:10.1038/s41467-020-15229-5

Wang, R., Mo, J., Luo, X., Zhang, G., Liu, F., and Luo, S. (2022). ORFV infection enhances CXCL16 secretion and causes oncolysis of lung cancer cells through immunogenic apoptosis. *Front Cell Infect Microbiol, 12*, 910466. doi:10.3389/fcimb.2022.910466

Wang, X., Shao, X., Gu, L., Jiang, K., Wang, S., Chen, J., et al. (2020). Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells. *J Cell Mol Med, 24*(7), 4286-4297. doi:10.1111/jcmm.15089

Watanabe, D., and Goshima, F. (2018). Oncolytic virotherapy by HSV. *Adv Exp Med Biol, 1045*, 63-84. doi:10.1007/978-981-10-7230-7\_4

Watanabe, K., Luo, Y., Da, T., Guedan, S., Ruella, M., Scholler, J., et al. (2018). Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. *JCI Insight, 3*(7), e99573. doi:10.1172/jci.insight.99573

Watanabe, N., McKenna, M. K., Rosewell Shaw, A., and Suzuki, M. (2021). Clinical CAR-T cell and oncolytic virotherapy for cancer treatment. *Mol Ther, 29*(2), 505-520. doi:10.1016/j.ymthe.2020.10.023

Wing, A., Fajardo, C. A., Posey, A. D., Jr., Shaw, C., Da, T., Young, R. M., et al. (2018). Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. *Cancer Immunol Res, 6*(5), 605-616. doi:10.1158/2326-6066.Cir-17-0314

Workenhe, S. T., and Mossman, K. L. (2014). Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. *Mol Ther, 22*(2), 251-256. doi:10.1038/mt.2013.220

Wu, F., Li, Y., Meng, Y., Cai, X., Shi, J., Li, J., et al. (2022). An ion-enhanced oncolytic virus-like nanoparticle for tumor immunotherapy. *Angew Chem Int Ed Engl, 61*(45), e202210487. doi:10.1002/anie.202210487

Xiao, J., Liang, J., Fan, J., Hou, P., Li, X., Zhang, H., et al. (2022). CDK4/6 inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T-cell activation in refractory glioblastoma. *Cancer Res, 82*(18), 3359-3374. doi:10.1158/0008-5472.Can-21-3656

Xie, S., Fan, W., Yang, C., Lei, W., Pan, H., Tong, X., et al. (2021). Beclin1‑armed oncolytic Vaccinia virus enhances the therapeutic efficacy of R‑CHOP against lymphoma in vitro and in vivo. *Oncol Rep, 45*(3), 987-996. doi:10.3892/or.2021.7942

Xu, B., Tian, L., Chen, J., Wang, J., Ma, R., Dong, W., et al. (2021). An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma. *Nat Commun, 12*(1), 5908. doi:10.1038/s41467-021-26003-6

Xu, Y., Chu, L., Yuan, S., Yang, Y., Yang, Y., Xu, B., et al. (2017). RGD-modified oncolytic adenovirus-harboring shPKM2 exhibits a potent cytotoxic effect in pancreatic cancer via autophagy inhibition and apoptosis promotion. *Cell Death Dis, 8*(6), e2835. doi:10.1038/cddis.2017.230

Yang, C., Hua, N., Xie, S., Wu, Y., Zhu, L., Wang, S., and Tong, X. (2021). Oncolytic viruses as a promising therapeutic strategy for hematological malignancies. *Biomed Pharmacother, 139*, 111573. doi:10.1016/j.biopha.2021.111573

Ye, T., Jiang, K., Wei, L., Barr, M. P., Xu, Q., Zhang, G., et al. (2018). Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells. *Am J Cancer Res, 8*(8), 1514-1527.

Zhang, C. D., Wang, Y. L., Zhou, D. M., Zhu, M. Y., Lv, Y., Hao, X. Q., et al. (2021). A recombinant Chinese measles virus vaccine strain rMV-Hu191 inhibits human colorectal cancer growth through inducing autophagy and apoptosis regulating by PI3K/AKT pathway. *Transl Oncol, 14*(7), 101091. doi:10.1016/j.tranon.2021.101091

Zhang, J., Lai, W., Li, Q., Yu, Y., Jin, J., Guo, W., et al. (2017). A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models. *Biochem Biophys Res Commun, 491*(2), 469-477. doi:10.1016/j.bbrc.2017.07.041

Zhu, Z., McGray, A. J. R., Jiang, W., Lu, B., Kalinski, P., and Guo, Z. S. (2022). Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways. *Mol Cancer, 21*(1), 196. doi:10.1186/s12943-022-01664-z